Development, validation, and preliminary phenotypic characterization of a Col6a3 knockout mouse model targeting exon 3

Abstract

Background: Most mutations in the COL6A3 gene lead to collagen VI-related myopathies. This is due to a reduced expression or mislocalization of the COL6A3 protein. Therefore, studying the consequence of knocking out the Col6a3 gene in mouse models is relevant, but the Col6a3 mouse models reported so far do not entirely abolish COL6A3 protein expression.

Methods: Here, we present the development, validation and preliminary phenotypic characterization of a novel CRISPR-based knockout mouse model targeting Col6a3 exon 3 (Col6a3^d3/d3).

Results: In this mouse model, Col6a3 mRNA is still expressed at a similar level to wild-type littermates, although the expected protein is undetectable by mass spectrometry. Histological analysis of Col6a3^d3/d3 quadriceps revealed an abnormally high frequency of muscle cells with internally nucleated muscle cells, consistent with a myopathy phenotype. Interestingly, Col6a3^d3/d3 mice are smaller in size, with their fat, muscle, and bone kept proportional compared to wild-type littermates.

Conclusions: In summary, we performed the validation and preliminary phenotypic characterization of a novel Col6a3 knockout mouse model that could be further characterized and used to study COL6A3 biology and model collagen VI-associated diseases.

Keywords

collagen VI / CRISPR / mass spectrometry / mouse model of human disease / myopathy

References

[1] Cescon M, Gattazzo F, Chen P, Bonaldo P. Collagen VI at a glance. J Cell Sci. 2015;128:3525-3531.

[2] Lamande SR, Bateman JF. Collagen VI disorders: insights on form and function in the extracellular matrix and beyond. Matrix Biol. 2018;71-72:348-367.

[3] Bonnemann CG. The collagen VI-related myopathies Ullrich congenital muscular dystrophy and Bethlem myopathy. Handb Clin Neurol. 2011;101:81-96.

[4] Lamande SR. Collagen VI muscle disorders: mutation types, pathogenic mechanisms and approaches to therapy. Adv Exp Med Biol. 2021;1348:311-323.

[5] Caria F, Cescon M, Gualandi F, et al. Autosomal recessive Bethlem myopathy: a clinical, genetic and functional study. Neuromuscul Disord. 2019;29:657-663.

[6] Foley AR, Hu Y, Zou Y, et al. Autosomal recessive inheritance of classic Bethlem myopathy. Neuromuscul Disord. 2009;19:813-817.

[7] Fitzgerald J, Rich C, Zhou FH, Hansen U. Three novel collagen VI chains, alpha4(VI), alpha5(VI), and alpha6(VI). J Biol Chem. 2008;283:20170-20180.

[8] Gara SK, Grumati P, Urciuolo A, et al. Three novel collagen VI chains with high homology to the alpha3 chain. J Biol Chem. 2008;283:10658-10670.

[9] Bonaldo P, Braghetta P, Zanetti M, Piccolo S, Volpin D, Bressan GM. Collagen VI deficiency induces early onset myopathy in the mouse: an animal model for Bethlem myopathy. Hum Mol Genet. 1998;7:2135-2140.

[10] Mohassel G, Rooney J, Zou Y, Bönnemann C. Col6A2 null mice are a new mouse model of collagen-VI related dystrophies and relevant to the human disease. Neuromuscul Disord. 2015;25:S266.

[11] Pan TC, Zhang RZ, Markova D, et al. COL6A3 protein deficiency in mice leads to muscle and tendon defects similar to human collagen VI congenital muscular dystrophy. J Biol Chem. 2013;288:14320-14331.

[12] Pan TC, Zhang RZ, Arita M, et al. A mouse model for dominant collagen VI disorders: heterozygous deletion of Col6a3 exon 16. J Biol Chem. 2014;289:10293-10307.

[13] Dickinson ME, Flenniken AM, Ji X, et al. High-throughput discovery of novel developmental phenotypes. Nature. 2016;537:508-514.

[14] Oh J, Kim CS, Kim M, Jo W, Sung YH, Park J. Type VI collagen and its cleavage product, endotrophin, cooperatively regulate the adipogenic and lipolytic capacity of adipocytes. Metabolism. 2021;114:154430.

[15] Lam DD, Williams RH, Lujan E, et al. Collagen VI regulates motor circuit plasticity and motor performance by cannabinoid modulation. J Neurosci. 2022;42:1557-1573.

[16] Marchadier A, Vidal C, Tafani JP, Ordureau S, Lédée R, Léger C. Quantitative CT Imaging for Adipose Tissue Analysis in Mouse Model of Obesity. SPIE Medical Imaging; 2011.

[17] Beaucage KL, Pollmann SI, Sims SM, Dixon SJ, Holdsworth DW. Quantitative in vivo micro-computed tomography for assessment of age-dependent changes in murine whole-body composition. Bone Rep. 2016;5:70-80.

[18] Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 2007;8:R19.

[19] Demichev V, Messner CB, Vernardis SI, Lilley KS, Ralser M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat Methods. 2020;17:41-44.

[20] Reimand J, Arak T, Adler P, et al. G:profiler-a web server for functional interpretation of gene lists (2016 update). Nucleic Acids Res. 2016;44:W83-W89.

[21] Leblanc S, Yala F, Provencher N, et al. OpenProt 2.0 builds a path to the functional characterization of alternative proteins. Nucleic Acids Res. 2024;52:D522-D528.

[22] Bonnemann CG. The collagen VI-related myopathies: muscle meets its matrix. Nat Rev Neurol. 2011;7:379-390.

[23] Chen P, Cescon M, Bonaldo P. Collagen VI in cancer and its biological mechanisms. Trends Mol Med. 2013;19:410-417.

[24] Vogel P, Read RW, Hansen GM, Powell DR. Histopathology is required to identify and characterize myopathies in high-throughput phenotype screening of genetically engineered mice. Vet Pathol. 2021;58:1158-1171.

[25] Noguchi S, Ogawa M, Malicdan MC, Nonaka I, Nishino I. Muscle weakness and fibrosis due to cell autonomous and non-cell autonomous events in collagen VI deficient congenital muscular dystrophy. EBioMedicine. 2017;15:193-202.

[26] de Greef JC, Hamlyn R, Jensen BS, et al. Collagen VI deficiency reduces muscle pathology, but does not improve muscle function, in the gamma-sarcoglycan-null mouse. Hum Mol Genet. 2016;25:1357-1369.

[27] Mohassel P, Rooney J, Zou Y, et al. Collagen type VI regulates TGFbeta bioavailability in skeletal muscle. 2023 bioRxiv.

[28] Bolduc V, Guirguis F, Lubben B, et al. A humanized knock-in Col6a1 mouse recapitulates a deep-intronic splice-activating variant. bioRxiv. 2024;2024.03.21.581572.

[29] López-Márquez A, Badosa C, Enjuanes L, et al. Generation and characterization of Col6a1 knock-in mice: a promising pre-clinical model for collagen VI-related dystrophies. 2025 bioRxiv, 2025.2003.2011.642560.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.